Monitoring and treating dormant tumors represents a major clinical challenge. We have recently found that early recurring tumors elicit an innate immune response that can be detected systemically. We also demonstrated that it may be possible to target minimal residual disease before or after immune evasion with carefully timed, rational therapeutic approaches.

Introduction: Glioblastoma multiforme (GBM) is a highly radioresistant cancer with low survival rate. Current therapy approaches have failed to treat GBM. The aim of this study was to assess how GBM tumors respond to combination of hyperthermia and radiotherapy. Materials and Methods:   In this study, 38 GBM patients were included. 19 patients were treated ...